Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early access study of ivosidenib in pretreated advanced cholangiocarcinoma
NL-OMON60087Phase 3Withdrawn
- Sponsor
- Servier
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Primary endpoints: Adverse events, Serious adverse events and 6 more. Planned start Jan 2023; status: withdrawn.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON60087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60087.